Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: A Danish drug utilization study

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 9, 2014, Pages 1413-1418

  Pottegard A ^a,b   Poulsen, B K ^c   Larsen, M D ^b   Hallas, J ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anticoagulants; Atrial fibrilliation; Coumarins; Dabigatran; Drug utilization

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CARBAMAZEPINE; CLARITHROMYCIN; DABIGATRAN ETEXILATE; NEW ORAL ANTICOAGULANT; PHENPROCOUMON; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; VITAMIN K GROUP;

ADULT; AGED; ARTICLE; DENMARK; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTITIONER; HEART ATRIUM FIBRILLATION; HOSPITAL PHYSICIAN; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PRESCRIPTION; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; CLINICAL PRACTICE; COHORT ANALYSIS; FACTUAL DATABASE; KAPLAN MEIER METHOD; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHYSICIAN; REGISTER; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; DATABASES, FACTUAL; DENMARK; DRUG UTILIZATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; REGISTRIES; VITAMIN K;

EID: 84908495430     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12662     Document Type: Article

References (17)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-98S.
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
3. ROCKET AF Study Investigators. Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159:340.e1-47.e1.
4. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
5. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GYH. American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e531S-75S.
6. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-47.
7. Danish Health and Medicines Authority. News about Pradaxa (dabigatran etexilate) and Xarelto (rivaroxaban). Danish Health and Medicines Authority (in Danish) https://sundhedsstyrelsen.dk/da/nyheder/2013/~/media/7AEFE599582A4F268E4F757B86D4799E.ashx. Accessed 19 June 2014.
8. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997; 44: 445-8.
9. WHO Collaborating Centre for Drug Statistics methodology. Guidelines for ATC Classification and DDD Assignment 2013. WHO Collaborating Centre for Drug Statistics methodology, 2012.
10. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39: 30-3.
11. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39: 22-5.
12. Thygesen LC, Daasnes C, Thaulow I, Brønnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health 2011; 39: 12-6.
13. Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 2012; 72: 1739-53.
14. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-51.
15. Department of Health and Human Services, FDA. Questions: Dabigatran [Internet]. http://www.fda.gov/downloads/Advisory Committees/CommitteesMeetingMaterials/Drugs/Cardiovascula randRenalDrugsAdvisoryCommittee/UCM247244.pdf. Accessed 19 June 2014.
16. Danish Health and Medicines Authority. Pradaxa - consider age and follow dose recommendations [Internet]. http://sundhedssty relsen.dk/en/news/2012/pradaxa-consider-age-and-follow-doserecommendations. Accessed 19 June 2014.
17. U.S. Food and Drug Administration. NDA 22-512 Dabigatran Efficacy Review [Internet]. http://www.fda.gov/downloads/advi sorycommittees/committeesmeetingmaterials/drugs/cardiovascula randrenaldrugsadvisorycommittee/ucm226704.pdf. Accessed 19 June 2014.